Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients.
Shuichi AokiFuyuhiko MotoiYoshiaki MurakamiMasayuki ShoSohei SatoiGoro HondaKenichiro UemuraKen-Ichi OkadaIppei MatsumotoMinako NagaiHiroaki YanagimotoMasanao KurataTakumi FukumotoMasamichi MizumaHiroki YamaueMichiaki Unnonull nullPublished in: BMC cancer (2019)
Decreased CA19-9 levels after neoadjuvant therapy predicts a better prognosis, with low incidence of hepatic recurrence after surgery.
Keyphrases
- rectal cancer
- end stage renal disease
- lymph node
- locally advanced
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- risk factors
- peritoneal dialysis
- coronary artery bypass
- stem cells
- cross sectional
- clinical trial
- squamous cell carcinoma
- mesenchymal stem cells
- percutaneous coronary intervention